Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease.
Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of …

Atorvastatin is a new 3‐hydroxy‐3‐methylglutaryl‐coenzyme A (HMG‐CoA) reductase
inhibitor that reduces plasma cholesterol by inhibiting cholesterol synthesis and increasing …

The objective of this study is to determine the relationships between plasma atorvastatin
concentrations, LDL (low‐density lipoprotein) cholesterol reduction, and atorvastatin dose; …

This study examined the pharmacokinetics, pharmacodynamics, and safety of atorvastatin,
an investigational inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) …

Synopsis Atorvastatin is a synthetic HMG-CoA reductase inhibitor which lowers plasma
cholesterol levels by inhibiting endogenous cholesterol synthesis. It also reduces …

Tolerance and pharmacokinetics after single‐dose administration of atorvastatin, an
investigational inhibitor of HMG‐CoA reductase, were examined in 22 healthy volunteers in …

Atorvastatin is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor. In dosages of 10 to 80 mg/day, atorvastatin reduces levels of total cholesterol, low …

Background. Patients with chronic renal failure commonly suffer from a secondary form of
complex dyslipidaemia, and may benefit from lipid‐lowering treatment. Atorvastatin has …

Pravastatin, one of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors (statins) widely used in the management of hypercholesterolaemia, has unique …

The hypolipidaemic agent pravastatin differs from other US Food and Drug Administration
(FDA)-approved HMG-CoA reductase inhibitors (eg lovastatin and simvastatin) because it …